{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:13:58Z","timestamp":1794348838696,"version":"4.9.0"},"publisher-location":"New York, NY","reference-count":42,"publisher":"Springer New York","isbn-type":[{"value":"9780387399775","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/978-0-387-39978-2_13","type":"book-chapter","created":{"date-parts":[[2007,8,21]],"date-time":"2007-08-21T02:30:49Z","timestamp":1187663449000},"page":"134-146","source":"Crossref","is-referenced-by-count":10,"title":["Gene Expression Profiling in Malignant Lymphomas"],"prefix":"10.1007","author":[{"given":"Sarah E.","family":"Henrickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"13_CR1","unstructured":"In: Jaffe ES, HNL Stein H, Vardiman JW, eds. World health organization classification of tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001."},{"key":"13_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.med.53.082901.103941","volume":"53","author":"L.M. Staudt","year":"2002","unstructured":"Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med 2002;53:303\u2013318.","journal-title":"Annu Rev Med"},{"key":"13_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1101\/sqb.1999.64.71","volume":"64","author":"A. Alizadeh","year":"1999","unstructured":"Alizadeh A, Eisen M, Davis RE et al. The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999;64:71\u201378.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.270.5235.467","volume":"270","author":"M. Schena","year":"1995","unstructured":"Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467\u2013470.","journal-title":"Science"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1471-4906(00)01792-0","volume":"22","author":"L.M. Staudt","year":"2001","unstructured":"Staudt LM. Gene expression physiology and pathophysiology of the immune system. Trends Immunol 2001;22:35\u201340.","journal-title":"Trends Immunol"},{"key":"13_CR6","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","volume":"95","author":"M.B. Eisen","year":"1998","unstructured":"Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863\u201314868.","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","volume":"194","author":"A. Rosenwald","year":"2001","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639\u20131647.","journal-title":"J Exp Med"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.1732008100","volume":"100","author":"G. Wright","year":"2003","unstructured":"Wright G, Tan B, Rosenwald A et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991\u20139996.","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR9","doi-asserted-by":"crossref","unstructured":"Braziel RM, Shipp MA, Feldman AL et al. Molecular diagnostics. Hematology (Am Soc Hematol Educ Program) 2003;279\u2013293.","DOI":"10.1182\/asheducation-2003.1.279"},{"key":"13_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"A.A. Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503\u2013511.","journal-title":"Nature"},{"key":"13_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A. Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937\u20131947.","journal-title":"N Engl J Med"},{"key":"13_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1074-7613(01)00194-7","volume":"15","author":"A.L. Shaffer","year":"2001","unstructured":"Shaffer AL, Rosenwald A, Hurt EM et al. Signatures of the immune response. Immunity 2001;15:375\u2013385.","journal-title":"Immunity"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00001622-200109000-00003","volume":"13","author":"B. Coiffier","year":"2001","unstructured":"Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325\u2013334.","journal-title":"Curr Opin Oncol"},{"key":"13_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"R.I. Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced nonHodgkin\u2019s lymphoma. N Engl J Med 1993;328:1002\u20131006.","journal-title":"N Engl J Med"},{"key":"13_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B. Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"13_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive nonHodgkins lymphoma","year":"1993","unstructured":"A predictive model for aggressive nonHodgkin\u2019s lymphoma. The International NonHodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987\u2013994.","journal-title":"N Engl J Med"},{"key":"13_CR17","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"R.E. Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861\u20131874.","journal-title":"J Exp Med"},{"key":"13_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M. Karin","year":"2002","unstructured":"Karin M, Cao Y, Greten FR et al. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301\u2013310.","journal-title":"Nat Rev Cancer"},{"key":"13_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3322\/canjclin.54.5.260","volume":"54","author":"B.D. Cheson","year":"2004","unstructured":"Cheson BD. What is new in lymphoma? CA Cancer J Clin 2004;54:260\u2013272.","journal-title":"CA Cancer J Clin"},{"key":"13_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"M.A. Shipp","year":"2002","unstructured":"Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68\u201374.","journal-title":"Nat Med"},{"key":"13_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2004-01-0240","volume":"105","author":"P.G. Smith","year":"2005","unstructured":"Smith PG, Wang F, Wilkinson KN et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K\/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005;105:308\u2013316.","journal-title":"Blood"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S. Monti","year":"2005","unstructured":"Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851\u20131861.","journal-title":"Blood"},{"key":"13_CR23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"S.S. Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159\u20132169.","journal-title":"N Engl J Med"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"R.N. Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840\u20131847.","journal-title":"Blood"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","volume":"100","author":"A. Krober","year":"2002","unstructured":"Krober A, Seiler T, Benner A et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410\u20131416.","journal-title":"Blood"},{"key":"13_CR26","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H. Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910\u20131916.","journal-title":"N Engl J Med"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"T.J. Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848\u20131854.","journal-title":"Blood"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","volume":"100","author":"D.G. Oscier","year":"2002","unstructured":"Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177\u20131184.","journal-title":"Blood"},{"key":"13_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","volume":"194","author":"U. Klein","year":"2001","unstructured":"Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625\u20131638.","journal-title":"J Exp Med"},{"key":"13_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood-2004-05-1715","volume":"105","author":"L. Chen","year":"2005","unstructured":"Chen L, Apgar J, Huynh L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105:2036\u20132041.","journal-title":"Blood"},{"key":"13_CR31","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","volume":"101","author":"A. Wiestner","year":"2003","unstructured":"Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944\u20134951.","journal-title":"Blood"},{"key":"13_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","volume":"363","author":"J.A. Orchard","year":"2004","unstructured":"Orchard JA, Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105\u2013111.","journal-title":"Lancet"},{"key":"13_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M. Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764\u20131775.","journal-title":"N Engl J Med"},{"key":"13_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa040857","volume":"351","author":"L.Z. Rassenti","year":"2004","unstructured":"Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893\u2013901.","journal-title":"N Engl J Med"},{"key":"13_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0140-6736(98)10117-4","volume":"353","author":"T. Stankovic","year":"1999","unstructured":"Stankovic T, Weber P, Stewart G et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26\u201329.","journal-title":"Lancet"},{"key":"13_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.V99.1.300","volume":"99","author":"T. Stankovic","year":"2002","unstructured":"Stankovic T, Stewart GS, Fegan C et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300\u2013309.","journal-title":"Blood"},{"key":"13_CR37","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood.V98.3.814","volume":"98","author":"A.R. Pettitt","year":"2001","unstructured":"Pettitt AR, Sherrington PD, Stewart G et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814\u2013822.","journal-title":"Blood"},{"key":"13_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2003-04-1161","volume":"103","author":"T. Stankovic","year":"2004","unstructured":"Stankovic T, Hubank M, Cronin D et al. Microarray analysis reveals that TP53-and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004;103:291\u2013300.","journal-title":"Blood"},{"key":"13_CR39","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2003-09-3236","volume":"104","author":"A. Rosenwald","year":"2004","unstructured":"Rosenwald A, Chuang EY, Davis RE et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428\u20131434.","journal-title":"Blood"},{"key":"13_CR40","first-page":"115","volume":"36","author":"E. Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115\u2013127.","journal-title":"Semin Hematol"},{"key":"13_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A. Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185\u2013197.","journal-title":"Cancer Cell"},{"key":"13_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","volume":"105","author":"A.M. Glas","year":"2005","unstructured":"Glas AM, Kersten MJ, Delahaye LJ et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301\u2013307.","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Microarray Technology and Cancer Gene Profiling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-0-387-39978-2_13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T16:56:52Z","timestamp":1605632212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-0-387-39978-2_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["9780387399775"],"references-count":42,"URL":"https:\/\/doi.org\/10.1007\/978-0-387-39978-2_13","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-0-387-39978-2","asserted-by":"object"}]},"subject":[]}}